Allergan Inc. Comments On Valeant Letter
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued the following statement in response to Valeant Pharmaceuticals International, Inc.’s (“Valeant”) October 27, 2014 letter to the Allergan Board of Directors.
Delivering value to Allergan’s stockholders remains the Board’s highest priority. If Valeant were to make an increased offer, the Board would carefully consider it and respond in due course. However, to date, as we have noted repeatedly, Valeant’s offers have been grossly inadequate and significantly undervalued Allergan.
Help employers find you! Check out all the jobs and post your resume.
Delivering value to Allergan’s stockholders remains the Board’s highest priority. If Valeant were to make an increased offer, the Board would carefully consider it and respond in due course. However, to date, as we have noted repeatedly, Valeant’s offers have been grossly inadequate and significantly undervalued Allergan.
Help employers find you! Check out all the jobs and post your resume.